- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02829931
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
January 18, 2023 updated by: H. Lee Moffitt Cancer Center and Research Institute
Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) Combined With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
The main purpose of this study is to evaluate the safety, and tolerability of nivolumab, ipilimumab, and bevacizumab given in combination with hypofractionated stereotactic re-irradiation of recurrent high grade gliomas.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of World Health Organization (WHO) Grade III or IV malignant glioma.
- Documented recurrence by diagnostic biopsy or contrast enhanced magnetic resonance imaging (MRI) performed within 28 days of entry in to the trial as per Response Assessment in Neuro-Oncology (RANO) criteria.
- Maximum diameter of enhancing tumor (target lesion) should be ≤ 4 cm.
- An interval of at least 6 months after the end of prior radiation therapy is required unless there is a new recurrence outside of the previous radiotherapy treatment field.
- Previous first line treatment with at least standard dose of radiotherapy (total dose ≥ 54 Gy) and temozolomide or Procarbazine, Lomustine, and Vincristine (PCV) for high grade glioma.
- An interval of ≥ 4 weeks since surgical resection prior to start of study treatment.
- An interval of ≥ 4 weeks after the last administration of any investigational agent, bevacizumab, or prior cytotoxic therapy.
- ≥18 years of age on day of signing informed consent.
- Karnofsky performance status of 70 or higher.
- Demonstrate adequate organ function. All screening labs should be performed within 28 days of treatment initiation.
- Resting baseline O2 saturation by pulse oximetry of ≥ 92% at rest.
- Must have recovered from the toxic effects of prior therapies (≤ Grade 1).
- Willing and able to provide written informed consent for the trial.
- Life expectancy ≥ 12 weeks
- Women of childbearing potential (WOCBP) should have a negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. WOCBP should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 5 months after the last dose of study medication.
- Males should agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy.
Exclusion Criteria:
- Has more than three recurrences of high grade glioma. Previous recurrences of low grade glioma is not considered.
- Has received re-radiation to recurrent disease (other than standard frontline adjuvant radiation therapy).
- Recurrent tumors near the brainstem and optic chiasm must not have received prior radiation therapy.
- Has infratentorial, or leptomeningeal evidence of recurrent disease.
- Has recurrent or persistent tumor (enhancing area) greater than 4 cm in maximum diameter.
- Has prior treatment with Gliadel unless it was administered as first line treatment and at least 3 months prior to study treatment.
- Is unable (due to existent medical condition) or unwilling to have a contrast enhanced MRI of brain.
- Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.
- Has a diagnosis of immunodeficiency or is receiving systemic immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Low doses of steroid therapy (dexamethasone 2mg/day or ≤ 10 mg/day prednisone equivalents) is allowed.
- Has had a prior chemotherapy, targeted small molecule therapy, or monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. This does not include lymphopenia.
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
- Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Potential participants with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Potential participants that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Potential participants with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study.
- Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
- Has an active infection requiring systemic therapy.
- Had major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of treatment on study.
- Requires escalating or chronic supraphysiologic doses of corticosteroids (>2 mg dexamethasone or > 10 mg/day prednisone equivalents) at the start day of treatment.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the participant, in the opinion of the treating investigator.
- Has prior history of uncontrolled hypertension, hypertensive crisis or hypertensive encephalopathy.
- Has history of non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to entry into the trial.
- Has history of gastrointestinal bleeding or any other hemorrhage/bleeding event ≥ grade 3 (CTCAE, v. 4) within 30 days prior to entry in to the trial.
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- Has received prior therapy with an anti-angiogenic agent such as bevacizumab, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C Virus (HCV) (e.g., HCV RNA [qualitative] is detected).
- Has received a live vaccine within 30 days prior to the first dose of trial treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination Therapy
Safety Cohort: The first 6 participants will receive Hypofractionated Stereotactic Irradiation (HFSRT) followed by Ipilimumab + Nivolumab + Bevacizumab. Dose Expansion Cohort: All 26 participants will be treated with Hypofractionated Stereotactic Irradiation (HFSRT), followed by Ipilimumab + Nivolumab +Bevacizumab |
Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.
Other Names:
Nivolumab intravenously (IV): 240 mg every (q) 3 weeks x 4 months followed by 480 mg X 4 months.
Other Names:
Bevacizumab intervenously (IV): 15 mg/kg every (q) 3 weeks when given with Ipilumumab and Nivolumab combination.
Dose changed to 10mg/kg every 2 weeks when given with Nivolumab only.
Other Names:
Ipilimumab 1mg/kg intervenously (IV) 200 mg (5 mg/mL) every (q) 3 weeks for 4 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Treatment Related Adverse Events
Time Frame: Up to 24 months
|
Safety and tolerability of nivolumab, given in combination with hypofractionated stereotactic re-irradiation of recurrent high grade gliomas.
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate
Time Frame: Up to 36 months
|
All participants will receive efficacy assessments with brain MRI at time points specified in Trial Flow Chart.
Cases of suspected radiologic disease progression will be confirmed by an MRI performed approximately 8 weeks after the initial radiological assessment of progression.
Immunotherapy Response Assessment in Neuro-Oncology (iRANO) and Response Assessment Criteria for High-Grade Gliomas (RANO Criteria) will be used for assessing the response to study treatment.
|
Up to 36 months
|
Overall Survival (OS) Rate at 6 Months
Time Frame: 6 months
|
OS, utilizing 95% confidence interval (95%CI).
|
6 months
|
Overall Survival (OS) Rate at 9 Months
Time Frame: 9 months
|
OS, utilizing 95% confidence interval (95%CI).
|
9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Solmaz Sahebjam, M.D., H. Lee Moffitt Cancer Center and Research Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 22, 2016
Primary Completion (Actual)
August 11, 2021
Study Completion (Actual)
November 22, 2022
Study Registration Dates
First Submitted
July 8, 2016
First Submitted That Met QC Criteria
July 8, 2016
First Posted (Estimate)
July 12, 2016
Study Record Updates
Last Update Posted (Estimate)
January 19, 2023
Last Update Submitted That Met QC Criteria
January 18, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Immune Checkpoint Inhibitors
- Nivolumab
- Bevacizumab
- Ipilimumab
Other Study ID Numbers
- MCC-18661
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Glioma
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Henry FriedmanCompletedGrade IV Malignant GliomaUnited States
-
Annick DesjardinsAmgenTerminated
-
Kentuckiana Cancer InstituteEisai Inc.UnknownNewly Diagnosed Supratentorial Malignant GliomaUnited States
-
AmgenCompletedGlioblastoma or Malignant GliomaUnited States, Australia, Netherlands, Germany, Spain, France
-
Duke UniversityMonteris MedicalWithdrawnGlioblastoma | Malignant Glioma of BrainUnited States
-
CellabMEDRecruitingRecurrent Malignant GliomaKorea, Republic of
-
Angiochem IncCompletedRecurrent or Progressive Malignant GliomaUnited States
-
University of ChicagoRecruitingMalignant Glioma of BrainUnited States
Clinical Trials on Hypofractionated Stereotactic Irradiation
-
Centre Oscar LambretNational Cancer Institute, FranceCompleted
-
Huashan HospitalActive, not recruiting
-
Andre Tsin Chih ChenActive, not recruitingRecurrent Glioblastoma MultiformeBrazil
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaTerminated
-
First People's Hospital of HangzhouHangzhou Cancer HospitalRecruitingNon Small Cell Lung Cancer | Brain Metastases | Stage IV Non-small Cell Lung CancerChina
-
H. Lee Moffitt Cancer Center and Research InstituteRecruiting
-
Chang Gung Memorial HospitalRecruitingBrain Metastases, AdultTaiwan
-
Barretos Cancer HospitalWithdrawnCancer | MetastasisBrazil
-
Tampere University HospitalCompletedProstate Neoplasms | Toxicity Due to RadiotherapyFinland
-
Fudan UniversityUnknown